Even with some high-profile hospital deals taking place in the first half of the year, merger activity across the broader healthcare industry has slowed a bit.CVS Health agreed to buy Oak Street Health in a deal worth more than $10 billion, but the pace of healthcare merger activity has slowed…
Source: www.chiefhealthcareexecutive.com – Read more
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
